Cash rewards with counseling could help prevent STIs

July 18, 2010

Berkeley - Giving out cash can be an effective tool in combating sexually transmitted infections in rural Africa, according to a new study conducted jointly by researchers at the University of California, Berkeley, the Development Research Group at the World Bank and the Ifakara Health Institute in Tanzania.

The study, to be presented Sunday, July 18, at the International AIDS Conference in Vienna, Austria, found that people who were offered up to $60 each over 12 months to stay free of STIs had a 25 percent lower prevalence of those infections after a year compared to those who were not eligible for the money.

"For many of our study participants, $60 represented about one-fourth of their reported annual income, so it was a significant incentive," said study author Will Dow, UC Berkeley professor of health economics. "The question we tested is whether the cash reward was enough of an incentive to reduce risky behavior and better take advantage of available health services. Although we cannot directly measure risky behavior, the fact that disease prevalence decreased suggests that the incentives worked."

Dow teamed up with Damien de Walque, a senior economist at the World Bank, and Rose Nathan, a senior research scientist at the Ifakara Health Institute, to test the conditional cash transfer program, an increasingly popular concept in the public health field that essentially rewards desirable behavior with money.

The year-long Rewarding STI Prevention and Control in Tanzania (RESPECT) study enrolled 2,399 adults from 10 villages in southwestern Tanzania. Rates of sexually transmitted infections in the region are comparable to the average rates for Africa.

Study participants were primarily 18 to 30 years old, a group considered at high risk for contracting STIs. They were randomly assigned to a no-payment control group, a low-payment group and a high-payment group. Over the year, participants in the low-payment group could get $10 every 4 months - up to $30 - if they tested negative for STIs, while those in the high-payment group could get $20 every 4 months, up to $60.

All participants were tested at the start of the study and every four months for the following year to detect a set of curable sexually transmitted infections, including chlamydia, gonorrhea and syphilis. Individual pre-test and post-test counseling was provided to study enrollees at each testing interval, and monthly group counseling sessions were also made available to all study participants to assist them in their efforts to reduce risky sexual behaviors.

HIV/AIDS was not linked to cash payments for both practical and ethical reasons, but the same risky sexual behaviors that increase the chances of the STIs tested also increase the risk of HIV, the researchers noted.

"Cash rewards have been proposed as a new HIV prevention tool to complement traditional approaches," said Dow. "New prevention tools are desperately needed since five people become newly infected with HIV for every two getting enrolled in new AIDS treatment programs. This study is the first to show that cash rewards can reduce STI prevalence, and is a key step in determining whether it is worthwhile to launch a larger study to test whether cash rewards could in fact slow the HIV epidemic."

At the end of the trial period, 9 percent of participants eligible for the $60 reward tested positive for the infections compared to 12 percent for the control group who were not eligible for payments. Any participant who tested positive for an STI during the study received free medical treatment and counseling.

"These are very encouraging results," said the World Bank's de Walque. "This was a proof-of-concept study that we now think should be replicated on a larger scale before concluding that this is an effective and feasible prevention approach."

Notably, the amount of cash offered mattered. The group that was eligible for the lower reward value had the same infection rate as the control group that received no payments. While the impact of the cash incentives did not differ between males and females, the impact was larger among people with lower incomes.
-end-
The project was funded by the World Bank, its Spanish Trust Fund for Impact Evaluation and, through the nonprofit Population Reference Bureau, the William and Flora Hewlett Foundation. The cash payments ended in May, and the researchers will test participants again next year to see if the cash group's infection rate will hold without cash incentives.

University of California - Berkeley

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.